Surging Growth in Pharma-Biotech and Active ETFs
Last month, pharmaceutical and biotech-related Exchange Traded Funds (ETFs) experienced impressive growth in the domestic stock market. Notably, Samsung Active Asset Management's KoAct BioHealthcare Active ETF achieved a remarkable 25.48% return, securing the top position. This ETF includes major stocks like ABL Bio, Alteogen, and Rigakem Bio, with ABL Bio's stock price driven by a technology transfer and joint R&D agreement worth approximately 3.8 trillion KRW with Eli Lilly.
Simultaneously, the domestic active ETF market in equity is rapidly expanding, with total net assets now surpassing 13 trillion KRW. This growth indicates the sustained interest in both U.S. big tech and domestic biotech stocks among market participants. The leadership shift from large-cap stocks such as Samsung Electronics and SK Hynix to KOSDAQ-focused IT and biotech stocks is notable. Additionally, thematic and overseas stock active ETFs are outperforming passive ETFs, achieving significant excess returns.
Related ETF
Related News
'Index Return + α' Active ETFs are Getting Bigger - Financial NewsThe size of active ETFs in the domestic exchange-traded fund market is rapidly increasing. In themes that have been strong this year, such as semiconductors, robotics, and biotechnology, active ETFs have maximized performance with high turnover and stock replacement strategies, showing a significant advantage over passive ones. Analyst Ha said, "It is a theme with a large stock price rise..."
Bio ETFs Thrived Amid 'November Adjustment in Korean Market', Sweeping Top Returns - Cookie NewsLast month, while the domestic stock market experienced a correction phase, pharmaceutical and bio-related ETFs showed strong upward trends. The investment industry noted this rising trend
Related ETF